University of Huddersfield Repository

Lomas, Emma C. and Maskell, Peter D.

Phenazepam: More information coming in from the cold

Original Citation


This version is available at http://eprints.hud.ac.uk/id/eprint/25902/

The University Repository is a digital collection of the research output of the University, available on Open Access. Copyright and Moral Rights for the items on this site are retained by the individual author and/or other copyright owners. Users may access full items free of charge; copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational or not-for-profit purposes without prior permission or charge, provided:

- The authors, title and full bibliographic details is credited in any copy;
- A hyperlink and/or URL is included for the original metadata page; and
- The content is not changed in any way.

For more information, including our policy and submission procedure, please contact the Repository Team at: E.mailbox@hud.ac.uk.

http://eprints.hud.ac.uk/
Phenazepam: More information coming in from the cold.

Phenazepam is a 1-4 benzodiazepine that was developed in 1975 in the former USSR and is used clinically as an anxiolytic [1], anticonvulsant, hypnotic and for the treatment of ethanol withdrawal [2]. Outside of the former soviet bloc there has been evidence of the abuse of phenazepam around the world since 1999 [3], with reports of overdoses, driving under the influence of drug (DUID) cases and also deaths [4-8]. As with other benzodiazepines the deaths have usually involved other drugs as well as phenazepam rather than phenazepam in isolation [9]. This has led to the control of phenazepam around the world. Due to the apparent persistence of phenazepam as a drug of abuse it is important to have knowledge of the pharmacokinetics, in relation to forensic toxicology, to determine the maximum length of time the drug could be detected after death. Also, the possibility of redistribution of the drug, which could affect the postmortem concentrations. The active metabolite of phenazepam, 3-hydroxy phenazepam and the parent drug are both full γ-aminobutyric acid type A (GABA<sub>A</sub>) receptor agonists [1] and are detectable in a variety of body fluids including subclavian, femoral and cardiac blood, urine, vitreous humour and tissues (thalamus, liver and psoas muscle) [9]. Due to phenazepam being developed in the former USSR there is limited information about it in the English literature with some publications being difficult to obtain. The current knowledge of phenazepam has been extensively reviewed in two fairly recent publications [1,8]. The limited information about the pharmacokinetics of phenazepam cited in these publications was only determined using two subjects (oral doses of 3mg and 5mg [10]) and intravenous/intramuscular injection in six subjects with a single dose of 2mg [11]. These studies gave a limited insight into the pharmacokinetics but was missing important information (such as the volume of distribution) and gave unclear results about the half-life (t½) with a range of 15h (via injection) and 60h (oral) [10, 11] . The authors recently obtained the Russian book “Phenazepam: 25 Years in Medical Practice” [12] containing a thesis based upon the pharmacokinetics of phenazepam which has allowed us to obtain further information [13]. In the thesis they describe a study where six patients were administered a single oral dose between 3 - 5mg and serial blood samples were taken and measured over 301 hours [13]. This new data has allowed us to update the information about phenazepam pharmacokinetics, particularly the information on the volume of distribution (V), half-life (t<sub>1/2</sub>), oral plasma clearance (CL) and absorption half-life (t<sub>1/2</sub>), which we have summarised below in table 1. It is interesting to note that the t½ of phenazepam appears to be significantly greater than 60 h reported in a previous study [10] with the new study giving a t½ (mean) of 140 h (range 48.8 – 301.0 h) [13]. This may account for the long duration of side effects observed in previous overdose cases [14]. This revised information will allow for more accurate interpretation of the drug in both the clinical setting for back calculations, which would be useful in jurisdictions that have blood levels for DUID offences such as Norway and the forensic setting in terms of postmortem phenazepam levels.
# Table 1 Pharmacokinetics of phenazepam in Humans

**Parameter** | **Value** | **Dose/route** | **Number of cases (n) [REF]**
--- | --- | --- | ---
Volume of Distribution (V) | 1.01 - 2.15 L/kg | 3 – 5 mg (oral) | 6 [13]
Absorption Half-Life (t1/2) | 0.26 – 1.18 h (median: 0.61 h) | 3 – 5 mg (oral) | 6 [13]
Elimination Half-Life (t1/2) – Injection | 14.9 h (IV), 15.6h (IM) | 2 mg (IV or IM) | 6 [11]
Elimination Half-Life (t1/2) - Oral | 49 - 301h (median: 103 h) | 3 – 5 mg (oral) | 6 [13]
Bioavailability (F) | 0.82 | 2 mg (IV or IM) | 6 [11]
Maximum plasma concentration (Cmax) | 0.024 µg/mL (3mg), 0.038 µg/mL (5mg) | 3 or 5 mg (oral) | 2 [10]
Time to maximum plasma concentration (Tmax) | ~2 - 4h | 3 or 5 mg (oral) | 2 [10]
Absorption rate constant (Ka) | 0.024 min⁻¹ (3 mg), 0.044 min⁻¹ (5 mg) | 3 or 5 mg (oral) | 2 [10]
Elimination rate constant (K) – Oral | 0.0002 min⁻¹ | 3 and 5 mg (Oral) | 2 [10]
Elimination rate constant (K) – Injection | 0.044 min⁻¹ (IM), 0.047 min⁻¹ (IV) | 2 mg (IV or IM) | 6 [11]
Plasma clearance (CL) – Injection | 220.43 ml/hr (IV), 267.93 ml/hr (IM) | 2 mg (IV or IM) | 6 [11]
Plasma clearance (CL) – Oral | 2.53 - 27.90 ml/kg/h (Median: 10.1 ml/kg/h) | 3-5 mg (oral) | 6 [13]
Constant Steady State (Css) | 157.29 µg/L | Repeated 1mg (IM) | 6 [11]

**References:**

12. Seredenin SB, Voronina TA, Neznamov GG, Zherdev VP. Phenazepam. 25 Years in Medical Practice 2007, Hayka, Moscow. [In Russian].